Overview

A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

Status:
TERMINATED
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
To compare the pairwise PK similarities between BAT3306, EU-Keytruda, and US-Keytruda, all administered with pemetrexed and carboplatin.
Phase:
PHASE3
Details
Lead Sponsor:
Bio-Thera Solutions
Treatments:
Carboplatin
pembrolizumab
Pemetrexed